¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"convergence theory of cancer"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
¿µ¹® cervix cancer ÇÑ±Û Àڱøñ¾Ï, ÀڱðæºÎ¾Ï
¼³¸í   
  ÀÚ±ÃÀÇ ¸ñÀº ÀÚ±ÃÀÌ Áú°ú ¿¬°áµÈ ºÎÀ§·Î ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇϴ ºÎÀ§ÀÌ´Ù. À̰÷ÀÇ »óÇǼ¼Æ÷¿¡¼­ ¹ß»ýÇϴ ¾ÏÀ» Àڱøñ¾ÏÀ̶ó°í ÇÑ´Ù.
  
  Àڱøñ¾ÏÀÇ ¹ß»ýÀ» »ìÆìº¸¸é ÀڱøñÀÇ »óÇǼ¼Æ÷°¡ ¿©·¯ °¡Áö Àڱؿ¡ ÀÇÇØ¼­ Á¤»ó¼¼Æ÷¿Í Â÷À̳ª´Â ¾Ï¼ºº¯È­¸¦ ÇÑ ¼¼Æ÷°¡ »ý±â°Ô µÈ´Ù. ÀÌ ¾Ï¼ºº¯È­¸¦ ÇÑ ¼¼Æ÷´Â Ã³À½¿¡´Â ÀڱøñÀÇ »óÇǼ¼Æ÷ÃþÀÇ ÀϺθ¦ ÀÌ·ç°í ÀÖ°Ô µÈ´Ù. ±×·¯´Ù°¡ Á¡Á¡ ´õ ÁøÇàÀÌ µÇ¸é ¾Ï¼º¼¼Æ÷°¡ Àڱøñ »óÇǼ¼Æ÷ÀÇ ¸ðµç ÃþÀ» ²Ëä¿ì°Ô µÈ´Ù. ±×¸®°í °è¼Ó ÁøÇàÇϸ頻óÇǼ¼Æ÷ÀÇ ¸Ç ¹Ø¿¡ Àִ ¹Ù´Ú¸·À» ¶Õ°í ¹öÆÀÁ¶Á÷À¸·Î Ä§À±ÇØ µé¾î°¡°Ô µÈ´Ù. ¾Ï¼ºº¯È­¸¦ ÇÑ ¼¼Æ÷°¡ ÀÚ±ÃÀÇ »óÇÇÃþÀÇ ÀϺθ¦ Ã¤¿ì´Â °ÍÀ» ÀڱøñÇü¼ºÀÌ»ó(cervical dysplasia)¶ó°í ÇÏ°í ¾Ï¼ºº¯È­¸¦ ÇÑ ¼¼Æ÷°¡ ÀÚ±ÃÀÇ »óÇÇÃþÀ» ¸ðµÎ Ã¤¿ö¹ö·Á Á¤»óÀûÀΠ¼¼Æ÷°¡ ¾ø´Â °æ¿ì¸¦ »óÇdz»¾ÏÁ¾(carcinoma in situ)¶ó°í ÇÑ´Ù. ±×¸®°í ¹Ù´Ú¸·À» ¶Õ°í ¹ØÀÇ ¹öÆÀÁ¶Á÷À¸·Î Ä§¹üÇØ ³ª°¡´Â °æ¿ì¸¦ Ä§À±¾Ï(invasive cancer)¶ó°í ÇÑ´Ù.
  
  Àڱøñ¾ÏÀº ¿©·¯ ¸íÀÇ »ó´ë¿Í ¼º°ü°è¸¦ °¡Áö´Â ¿©ÀÚ, ±×¸®°í Ã¹ ¼º°æÇèÀÇ ³ªÀ̰¡ ¾î¸° ¿©ÀÚ¿¡°Ô¼­ ÈçÇÏ°í ¶Ç »çȸÀû, °æÁ¦Àû ¼öÁØÀÌ ³·Àº »ç¶÷¿¡°Ô¼­ Àß °É¸®´Â °ÍÀ¸·Î µÇ¾î ÀÖ´Ù. ÀÌ·± °ÍÀ¸·Î ¹Ì·ç¾î Àڱøñ¼¼Æ÷ÀÇ ¾Ï¼ºº¯È­¿¡´Â ¼ºº´°ú °°Àº °¨¿°ÀÌ Áß¿äÇÒ °ÍÀ¸·Î »ý°¢µÇ°í, ¶Ç ¸î°¡Áö ¹ÙÀÌ·¯½ºÀÇ °¨¿°ÀÌ Àڱøñ¾ÏÀÇ ¿øÀÎÀ̶ó´Â °ÍÀÌ ¹àÇôÁ® ÀÖ´Ù.
  
  Àڱøñ¾ÏÀÇ Áø´Ü¹æ¹ýÀ¸·Î´Â Áú¼¼Æ÷°Ë»ç, ÄÝÆ÷½ºÄÚÇÇ, »ý°Ë(biopsy) µîÀÌ ÀÖ´Ù. ¼¼Æ÷°Ë»ç¶õ Á¶±âÁø´Ü ¸ñÀûÀ¸·Î °¡Àå ¸¹ÀÌ »ç¿ëµÇ´Â ¹æ¹ýÀ¸·Î ¼ØºÀÀ¸·Î ÀڱøñÀ»¸¦ ¹®Áú·¯¼­ Àڱøñ»óÇǼ¼Æ÷¸¦ ¾ò°í À̰ÍÀ» Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© »óÇǼ¼Æ÷ÀÇ º¯È­¸¦ º¸´Â °ÍÀÌ´Ù. ÄÝÆ÷½ºÄÚÇǶõ ÀÚ±ÃÀÇ ¸ñÀ» 4~10¹è Á¤µµ È®´ëÇØ¼­ º¸´Â ÀÏÁ¾ÀÇ È®´ë°æ°Ë»çÀ¸·Î Àڱøñ¾ÏÀ¸·Î ÀÎÇÑ ÀڱøñÀÇ º´Àûº¯È­¸¦ °üÂûÇÏ¿© Áø´ÜÇϴ °ÍÀÌ´Ù. »ý°Ë¶õ Áø´ÜÀ» À§Çؼ­ Á÷Á¢ ÀڱøñÀÇ Á¶Á÷À» ¶¼¾î Ã¤ÃëÇÏ¿© Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© Áø´ÜÇϴ °ÍÀ¸·Î °¡Àå Á¤È®ÇÑ Áø´Ü¹ýÀÌ´Ù.
  
  Ä¡·á·Î´Â º´ÀÇ ÁøÇàÁ¤µµ¿¡ µû¶ó ´Ù¸£°ÚÁö¸¸ ¾ÏÀÇ ÁøÇàÀÌ °ÅÀÇ ¾ø¾î Çü¼ºÀÌ»óÀ̳ª Á¦ÀÚ¸®¾ÏÁ¾ ¶Ç´Â ¾ÆÁÖ Á¶±Ý Ä§À±ÇÏ¿´À» °æ¿ì¿¡´Â ¼ö¼úÀû¿ä¹ýÀ¸·Î ÀÚ±ÃÀ» ÀûÃâÇϴ °ÍÀÌ Ä¡·áÀÇ ¿øÄ¢ÀÌ°í ¸¹Àº ÁøÇàÀ» º¸¿© ´Ù¸¥ Á¶Á÷À¸·Î ¾ÏÀǠħÀ±ÀÌ ÀÖÀ» °æ¿ì¿¡´Â ¹æ»ç¼± Ä¡·á¸¦ ¿øÄ¢À¸·Î ÇÑ´Ù.
¿µ¹® advanced cancer ÇÑ±Û ÁøÇà¾Ï
¼³¸í   
  Á¶±â¾Ï¿¡ ´ëÇÑ ¸»·Î ¾ÏÀÇ °æ°ú°¡ ÁøÇàµÈ °ÍÀ» ¸»ÇÑ´Ù.
¿µ¹® lung cancer ÇÑ±Û Æó¾Ï
¼³¸í   
  ÇãÆÄ¿¡ »ý±â´Â ¾Ç¼ºÁ¾¾çÀÌ´Ù. °¡Àå ¿¹Èİ¡ ³ª»Û Á¾¾çÁßÀÇ Çϳª·Î½á Á¶±â¹ß°ßÀÌ ¾î·Æ°í Áõ¼¼ ¶ÇÇÑ ´Ê°Ô ³ªÅ¸³ª¼­, ±× Á¾¾çÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£³ª Ä¡·áÈÄ¿¡µµ ´ë°³ 8%¸¸ÀÌ 5³â »ýÁ¸ÀÌ °¡´ÉÇÑ ¾Ç¼ºÁ¾¾çÀÌ´Ù. À¯¹ßÀÎÀڷδ ´ëÇ¥ÀûÀ¸·Î ´ã¹è°¡ ¾Ë·ÁÁ® ÀÖÀ¸¸ç, À¯ÀüÀûÀΠ¿ä¼Òµµ ¾î´À Á¤µµ ±â¿©Çϴ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.
¿µ¹® cancer chemotherapy ÇÑ±Û Ç×¾ÏÈ­Çпä¹ý
¼³¸í   
  È­ÇÐÀû ¹°ÁúÀ» ÀÌ¿ëÇÏ¿© ¾ÏÀ» Ä¡·áÇϴ °ÍÀ» ¸»ÇÑ´Ù. À̶§ »ç¿ëµÇ´Â ¹°ÁúÀ» Ç×¾ÏÁ¦¶ó°í ÇÑ´Ù. ÀÌ»óÀûÀΠÇ×¾ÏÁ¦´Â Á¤»óÀûÀΠ¼¼Æ÷¿¡´Â ÀÌ»óÀÌ ¾ø°í ´ÜÁö ¾Ï¼¼Æ÷¿¡¸¸ Ä¡¸íÀûÀΠȿ°ú¸¦ ³ªÅ¸³»¾î¾ß ÇÑ´Ù. ÀÌ·¸°Ô ÇÏ·Á¸é ¾Ï¼¼Æ÷¸¸ÀǠƯÀÌÇѠƯ¼ºÀ» ÀÌÇØÇÏ°í ±×°÷¿¡¸¸ ÀÛ¿ëÇϴ ¾à¹°À» °³¹ßÇÏ¿©¾ß ÇÑ´Ù. ÃÖ±Ù ´ëºÎºÐÀÇ Ç×¾ÏÁ¦´Â ¾Ï¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ¿ùµîÈ÷ Áõ½ÄÀ» »¡¸®ÇѴٴ Ư¼ºÀ» ÀÌ¿ëÇϰí ÀÖ´Ù. Áõ½ÄÀÌ ºü¸£´Ù´Â °ÍÀº À¯ÀüÁ¤º¸¸¦ °¡Áö°í Àִ DNAÀÇ º¹Á¦°¡ ºü¸£´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ¸¸¾à DNAÀÇ º¹Á¦¸¦ ¹æÇØÇÑ´Ù¸é Áõ½ÄÀÌ ¾ÆÁÖ ºü¸¥ ¾Ï¼¼Æ÷¿¡°Ô´Â Ä¡¸íÀûÀÌÁö¸¸ ¿µ¿øÈ÷ Áõ½ÄÀ» ÇÏÁö ¾Ê´Â(DNAÀÇ º¹Á¦°¡ °ÅÀÇ ÇÊ¿ä¾ø´Â)½Å°æ¼¼Æ÷³ª Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿¡ ºñÇØ¼­ ¾ÆÁÖ ´À¸° Á¤»ó¼¼Æ÷¿¡¼­´Â °ÅÀÇ ¿µÇâÀ» ÁÖÁö ¸øÇÑ´Ù. ÇÏÁö¸¸ ½Åü¿¡¼­µµ Á¤»óÀûÀ¸·Î Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿Í ºñ½ÁÇÑ ¼öÁØÀ¸·Î ÀϾ´Â ¼¼Æ÷°¡ Àִµ¥ ±×°ÍÀº ¸Ó¸®Ä«¶ôÀ» ¸¸µå´Â ¸ð³¶¼¼Æ÷¿Í ¼ÒÈ­°üÀÇ Á¡¸·À» ÀÌ·ç´Â ¼¼Æ÷¿Í Ç÷¾×ÀÇ ¼¼Æ÷¸¦ ¸¸µå´Â °ñ¼ö ¼¼Æ÷ÀÌ´Ù. ±×·¯¹Ç·Î Ç×¾ÏÁ¦¸¦ »ç¿ëÇÒ °æ¿ì ÀÌ·± ¼¼Æ÷°¡ ¾Ï¼¼Æ÷¿Í ¸¶Âù°¡Áö·Î Ä¡¸íÀûÀΠ¿µÇâÀ» ÀÔÀ» °ÍÀº ´ç¿¬ÇÏ´Ù(±×·¡¼­ Ç×¾ÏÁ¦ Ä¡·á½Ã¿£ ¸Ó¸®°¡ ºüÁö°í ¼ÒÈ­ºÒ·®ÀÌ À߿´Ù).
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • social learning theory
    »çȸÇнÀÀÌ·Ð
  • template theory
    Ç×ü»ý»êÁö½Ã¼³, ÅÆÇø´¼³
  • accommodative convergence
    Á¶Àý´«¸ðÀ½
  • convergence
    1. ´«¸ðÀ½, ÆøÁÖ 2. ½Å°æÀڱظðÀ½
  • convergence amplitude
    ´«¸ðÀ½´É·Â
  • convergence excess
    ´«¸ðÀ½°ú´Ù
  • convergence insufficiency
    ´«¸ðÀ½ºÎÀü, ÆøÁÖºÎÀü
  • convergence insufficiency exotropia
    ´«¸ðÀ½ºÎÁ·¿Ü»ç½Ã, ÆøÁÖºÎÁ·¿Ü»ç½Ã
  • convergence nystagmus
    ´«¸ðÀ½´«¶³¸², ÆøÁÖ¾ÈÁø
  • convergence palsy
    ´«¸ðÀ½¸¶ºñ, ÆøÁÖ¸¶ºñ
  • convergence reflex
    ´«¸ðÀ½¹Ý»ç
  • convergence-retraction nystagmus
    ´«¸ðÀ½ÈÄÅð´«¶³¸², ÆøÁÖÈÄÅð¾ÈÁø
  • fusional convergence
    À¶ÇÕ´«¸ðÀ½
  • near convergence
    ±ÙÁ¢´«¸ðÀ½
  • negative convergence
    À½¼º´«¸ðÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • metastatic cancer
    ÀüÀ̾Ï
  • primary cancer
    ¿ø¹ß¾Ï
  • prostatic cancer
    Àü¸³»ù¾Ï
  • renal cancer
    ÄáÆÏ¾Ï, ½ÅÀå¾Ï
  • thyroid papillary cancer
    °©»ó»ùÀ¯µÎ¾ÏÁ¾
  • undifferentiated cancer
    ¹ÌºÐÈ­¾Ï
  • cancer pain
    ¾ÏÅëÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • positive convergence
    ¾ç¼º´«¸ðÀ½
  • prism convergence
    ÇÁ¸®Áò´«¸ðÀ½
  • proximal convergence
    ±ÙÁ¢´«¸ðÀ½
  • relative convergence
    »ó´ë´«¸ðÀ½
  • tonic convergence
    ±äÀå´«¸ðÀ½
  • voluntary convergence
    ¼öÀÇ´«¸ðÀ½
  • hilum convergence sign
    ÇãÆÄ¹®¸ðÀÓ¡ÈÄ, Æó¹®¸ðÀÓ¡ÈÄ
  • advanced cancer
    ÁøÇà¾Ï
  • breast cancer
    À¯¹æ¾Ï
  • cancer
    ¾Ï
  • cancer pain
    ¾ÏÅëÁõ
  • cancer registry
    ¾Ïµî·Ï»ç¾÷ºÎ
  • cauliflower cancer
    ¾ç¹èÃ߲ɾÏ
  • conjugal cancer
    ºÎºÎ¾Ï
  • corset cancer
    ÄÚ¸£¼Â¾Ï
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adsorption theory
    ÈíÂø¼³, Èí¼ö¼³.
  • aging,free radical theory
    À¯¸®±â ¼³(ë´×îÐñàã)
  • alternation theory
    ±³¹ø¼³(ÎßÛãæò).
  • gate control theory
    (°ü)¹®Á¶Àý¼³(μڦðàï½àã).
  • general system theory
    ÀϹÝü°è(ÀÌ)·Ð(ìéÚõô÷ͧìµÖå)
  • germ line theory
    ³»¸²¹°·Á¹Þ±â¼³ (Ç×ü´Ù¾ç¼ºÀÇ)
  • glucostat theory
    Ç×´ç±â¼³(ù÷ÓØÐñæò).
  • instinct theory
    º»´É ÀÌ·Ð
  • instructive theory of antibody production
    Áö·É¼³ (Ç×ü»ý»ê)
  • personality structure, Jungian theory
    Àΰݱ¸Á¶
  • personality theory
    ÀΰÝÀÌ·Ð
  • place theory
    ºÎÀ§¼³(Ý»êÈæò).
  • polychromatic theory
    ´Ù»ö¼³
  • psychoanalytic theory
    Á¤½ÅºÐ¼®ÇÐÀÌ·Ð(¡­ùÊìµÖå).
  • quantum theory
    ¾çÀÚ·Ð.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • convergence spasm
    ´«¸ðÀ½¿¬Ãà, ÆøÁÖ¿¬Ãà
  • convergence-evoked nystagmus
    ´«¸ðÀ½¿øÀξÈÁø, ÆøÁÖ¿øÀξÈÁø
  • convergence-retraction nystagmus
    ´«¸ðÀ½ÈÄÅð¾ÈÁø, ÆøÁÖÈÄÅð¾ÈÁø
  • far point of convergence
    ´«¸ðÀ½¿øÁ¡, ÆøÁÖ¿øÁ¡
  • fatigue of convergence
    ´«¸ðÀ½ÇÇ·Î, ÆøÁÖÇÇ·Î
  • fusional convergence
    À¶ÇÕ¼º´«¸ðÀ½, À¶ÇÕ¼ºÆøÁÖ
  • hilum convergence sign
    Æó¹® ¼ö·Å ¡ÈÄ
  • hilum convergence sign
    Æó¹®¼ö·Å¡ÈÄ.
  • insufficiency of convergence
    ´«¸ðÀ½ºÎÁ·, ÆøÁÖºÎÁ·
  • near convergence
    ±ÙÁ¢(½Ã)´«¸ðÀ½, ±ÙÁ¢(½Ã)ÆøÁÖ
  • near point of convergence
    ´«¸ðÀ½±ÙÁ¡, ÆøÁÖ±ÙÁ¡
  • negative convergence
    À½¼º´«¸ðÀ½, À½¼ºÆøÁÖ(~ÜßñÍ).
  • paralysis of convergence
    ´«¸ðÀ½¸¶ºñ
  • point of basal convergence
    ±âÃÊÆøÁÖÁ¡(Ðñõ¨ÜßñÍïÇ).
  • point of convergence
    ÆøÁÖÁ¡(ÜßñÍïÇ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • elective theory
    ¼±Å÷Ð(àÔ÷ÉÖå)
  • error theory
    ¿À·ù ÀÌ·Ð (è¦×½×âÖå)
  • eversion theory
    ¿Ü¹øÀÌ·Ð (èâÛè×âÖå)
  • evolution theory
    ÁøÈ­·Ð(òäûùÖå)
  • exhaustion theory
    °í°¥ ÀÌ·Ð (ͽÊä×âÖå)
  • factor theory
    ÀÎÀÚ ÀÌ·Ð(ì×í­×âÖå)
  • fluctuation theory
    ¿äµ¿ ÀÌ·Ð(èôÔÑ×âÖå)
  • frozen accident theory
    »ç°í µ¿°á ÀÌ·Ð(ÞÀͺÔÐÌ¿×âÖå)
  • germ-line theory
    ¹èÀÚ°è¿­ ÀÌ·Ð(ÛÏí­Í§Öª×âÖå)
  • hit theory
    °¡°Ý ÀÌ·Ð(ʥ̪×âÖå)
  • imbalance theory
    ºÒ±ÕÇü ÀÌ·Ð(ÝÕгû¬×âÖå)
  • immune surveillance theory
    ¸é¿ª °¨½Ã ÀÌ·Ð(Øóæ¹ÊøãÊ×âÖå)
  • immunological surveillance theory
    ¸é¿ª °¨½Ã ÀÌ·Ð(Øóæ¹ÊøãÊ×âÖå)
  • inchworm theory
    ÀÚ¹ú·¹ ÀÌ·Ð(×âÖå)
  • induced fit theory
    À¯µµÀûÇÕÀÌ·Ð(ë¯Óôîêùê×âÖå)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TSD target-skin distance; Tay-Sachs disease; theory of signal detectability
AC/A accommodative convergence/accommodation [ratio]
CI cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar...
conv convalescence, convalescent, convalescing; convergence, convergent; convulsions, convulsive
converg convergence, convergent
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TPB Theory of Planned Behavior
TRA Theory of Reasoned Action
A.G.C. Advanced Gastric Cancer
ATBC Alpha-Tocopherol Beta-Carotene Cancer Prevention
ACS American Cancer Society
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bladder cancer
    ¹æ±¤ ¾Ï
  • breast cancer
    À¯¹æ ¾Ï
  • cancer aquaticus
    ¼ö¾Ï, ±«Àú¼º ±¸³»¿°
  • cancer cell
    ¾Ï ¼¼Æ÷
    Á¤»óÀÎ Á¶Á÷ ¼¼Æ÷°¡ ¾î¶² ¿øÀÎÀ¸·Î ¹«Á¦ÇÑ Áõ½ÄÇÏ¿© ±× »ýüÀÇ »ýȰÇö»óÀ̳ª ÁÖÀ§ÀÇ Á¶Á÷ »óÅ µî¿¡ °ü°è¾øÀÌ ±Þ¼ÓÇÑ ¹ßÀ°À» °è¼ÓÇÏ¿© ¸¶Ä§³»´Â »ý¸íÀ» ²÷°Ô ÇÏ´Â ¾Ç¼ºÀÇ ½Å»ý¹°À̶ó°íµµ º¼ ¼ö ÀÖ´Â ¼¼Æ÷. ¼¼Æ÷ÇÐÀûÀ¸·Î º¸¸é ±× ¸ð¾çÀ̳ª Å©±â°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ´Ù¼Ò º¯È­µÇ¾î ÀÖ´Ù. Áï, ÇÙÀº ¿°»öü°¡ ¸¹°í, ÇÙÀÇ ¿øÇüÁú¿¡ ´ëÇÑ ºñ°¡ Å©¸ç, ÇÙ¼Òü¸¦ °¡Áö°í, ÀÚÁÖ ÇÙ ºÐ¿­»óÀ» ³ªÅ¸³½´Ù. À̰ÍÀ» ÀÌÇü¼ºÀ̶ó°í ÇÑ´Ù. ÀÌÇü¼ºÀÌ °­ÇÑ °ÍÀÌ ¾Ï ¼¼Æ÷ÀÇ Æ¯Â¡ÀÌ´Ù. À̰ÍÀ» ÀÌ¿ëÇÑ °ÍÀÌ ¼¼Æ÷ÁøÀ̸ç, À§¾Ï µî ¸ðµç ¾ÏÀÇ Á¶±â Áø´Ü¿¡ Å« ¿ªÇÒÀ» Çϰí ÀÖ´Ù. Á¤»ó ¼¼Æ÷°¡ ¾î¶»°Ô ÇØ¼­ ¾Ï ¼¼Æ÷·Î º¯Çϴ°¡´Â ºÒ¸í·áÇÑ Á¡ÀÌ ¸¹Áö¸¸, È÷¸£È¿ÀÇ Àڱؼ³Àº À¯¸íÇÏ´Ù. À̰ÍÀº È­ÇÐÀû, ±â°èÀû, ¹°¸®Àû µîÀÇ ¸¸¼º ÀÚ±ØÀÌ ÀÛ¿ëÇÏ´Â °÷¿¡ ¾ÏÀÌ ¹ß»ýÇÑ´Ù´Â ¼³ÀÌ´Ù. ¹ÙÀÌ·¯½º¿ÍÀÇ °ü°èµµ ±Ù³â¿¡ ÁÖ¸ñÀ» ²ø¾î, F.P. ¶ó¿ì½ºÀÇ ´ßÀÇ À°Á¾ ¹ÙÀÌ·¯½º³ª R.E. ¼îÇÁÀÇ Åä³¢ÀÇ À¯µÎÁ¾ ¹ÙÀÌ·¯½º´Â À¯¸íÇÏÁö¸¸, Àΰ£ÀÇ ¾Ï°ú È®½ÇÇÏ°Ô °ü°è¸¦ °®´Â ¹ÙÀÌ·¯½º´Â ¾ÆÁ÷ ¹ß°ßÇÏÁö ¸øÇϰí ÀÖ´Ù. ¾Ï ¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿Í ´Ù¸¥ Á¡Àº ÀÚÀ²ÀûÀ¸·Î Áõ½ÄÇϰí ÁÖÀ§ÀÇ Á¶Á÷À» ÆÄ±«ÇÏ¿© ħÀ±¼ºÀ¸·Î ¹ßÀ°ÇÏ´Â °Í, ¾Ï ¼¼Æ÷°¡ À¯¸®µÇ¾î ¸²ÇÁÇ༺, Ç÷Ç༺À¸·Î ¿ø°Ý Àå±â¿¡ ÀüÀÌÇÏ´Â °Í, ÆÄÁ¾À̶ó ÇÏ¿© º¹°­³»³ª Èä°­³»ÀÇ Àå±âÀÇ ¾Ï¿¡¼­´Â ¾Ï ¼¼Æ÷°¡ À帷¿¡ µµ´ÞÇÏ¸é º¹¸·À̳ª È丷¿¡ ºÎÂøÇÏ¿© ¹ßÀ°À» °è¼ÓÇÏ´Â °Í µîÀÌ´Ù. ÀÌ·± Ư¼º ¶§¹®¿¡ ¾ÏÀÇ Ä¡·á°¡ º¹ÀâÇØÁö°í Àç¹ßµÇ±â ½±´Ù. µû¶ó¼­ ¾ÏÀ» °íÄ¡·Á¸é ¾Ï ¼¼Æ÷°¡ ÀÌ·± Ư¼ºÀ» ÃæºÐÈ÷ ¹ßÈÖÇÏÁö ¸øÇÏ´Â Á¶±â¿¡ ¹ß°ß, Ä¡·áÇØ¾ß ÇÑ´Ù.
  • cancer en cuirasse
    °©¿Ê ¾Ï, Àå°© ¾Ï, Æ÷ÇÇ ¾Ï
    ÈäºÎ ÇǺο¡ ÀÚÁÖ ¹ß»ýÇÏ´Â ¾ÏÁ¾.
  • cancer nest
    ¾Ï¼Ò
    ¾Ï ¹ßÀ°ºÎ¿¡¼­ º¼ ¼ö ÀÖ´Â ±¸½É¼ºÀ¸·Î ¹è¿­µÈ ¾Ï ¼¼Æ÷ÀÇ µ¢¾î¸®.
  • cancer suppressor gene
    ¾Ï ¾ïÁ¦ À¯ÀüÀÚ
  • esophageal cancer
    ½Äµµ ¾Ï
  • head and neck cancer
    µÎ°æºÎ ¾Ï
    ¸Ó¸®¿Í ¸ñ ºÎÀ§¿¡ »ý±â´Â ¾Ï.
  • latent prostatic cancer
    Àü¸³»ù ÀáÀç ¾Ï
  • lip cancer
    ÀÔ¼ú ¾Ï
  • mammary cancer
    À¯¾Ï
    Á¥»ù¿¡¼­ ¹ß»ýÇÏ´Â À¯¹æÀÇ ¾Ï. Àڱ⠰˻ç¹ýÀ¸·Î Á¶±â ¹ß°ßÀÌ °¡´ÉÇÏ´Ù. ³²¼ºÀÇ À¯¹æ ¾ÏÀº ¿©¼ºÀÇ ¾à 1/100·Î ¸Å¿ì µå¹°´Ù. ¹éÀÎ, ƯÈ÷ ºÏÀ¯·´°èÀÇ ¿©¼º¿¡°Ô ¸¹Àºµ¥, ÇÏ¿ÍÀÌ °ÅÁÖÀÚÀÇ Á¶»ç
  • mouth cancer
    ±¸°­ ¾Ï
  • occupational cancer
    Á÷¾÷ ¾Ï
  • oral cancer
    ±¸°­ ¾Ï
    Àüü ¾Ï ¹ß»ý ºóµµ¿¡¼­ ¾à 3¡­4%¸¦ Â÷ÁöÇÏ´Â ±¸°­ ¾ÏÀº Çô, »´, Ä¡ÁÖÁ¶Á÷, ¶Ç´Â ±¸ÀεÎÀÇ ¾î´À ºÎÀ§¿¡µµ ħ¹üÇÒ ¼ö ÀÖ´Ù. ÀÌ´Â ±¸°­ ³»ÀÇ ¹ß»ý À§Ä¡¿¡ µû¶ó ´Þ¶óÁö±â´Â ÇÏÁö¸¸ ´ë°³ ¿©ÀÚº¸´Ù´Â ³²ÀÚ¿¡°Ô¼­ ¾à 2~6¹è ¸¹ÀÌ ¹ß»ýÇÏ¸ç ¿ì¸® ³ª¶ó¿¡¼­´Â 1³â¿¡ ¾à õ ¸í ³»Áö ÀÌ Ãµ¸íÀÇ »õ·Î¿î ±¸°­ ¾Ï ȯÀÚ°¡ ¹ß»ýÇϱ⠶§¹®¿¡ ±¸°­ ¾ÏÀ¸·Î Åõº´ ÁßÀΠȯÀÚ¸¸µµ ¼ö ¸¸ ¸í¿¡ À̸¥´Ù. 1996³â¿¡ ½ÃÇàÇÑ ÈÄÇ⼺ ¿¬±¸¿¡ ÀÇÇϸé Àüü ±¸°­ ¾Ï ȯÀÚÀÇ Æò±Õ 5³â »ýÁ¸À²Àº ¾à 46%·Î ¹Ý ÀÌ»óÀÇ È¯ÀÚ°¡ 5³â À̳»¿¡ »ç¸ÁÇÏ´Â °ÍÀ¸·Î Á¶»çµÈ¹Ù ÀÖ´Ù. ±¸°­ ¾ÏÀÇ À¯º´·üÀº ¿¬·É Áõ°¡¿Í °ü·ÃÀÌ ÀÖ´Ù. 40¼¼ ÀÌÈÄ¿¡ ¹ß»ý·üÀÌ ±ØÀûÀ¸·Î Áõ°¡Çϱ⠽ÃÀÛÇÏ¿© 60¼¼ÀÇ ¿¬·É¿¡¼­ ÀÏÁ¤ÇÑ À¯Áö °î¼±À» Çü¼ºÇÑ´Ù. ¾î¶² ¿ä¼Ò°¡ ±¸°­ ¾Ï ¹ß»ý¿¡ °¡Àå Å« ¿µÇâÀ» ³¢Ä¡´Â°¡¿¡ ´ëÇÑ ¹®Çå ¿¬±¸¿¡¼­ ´ã¹è¿Í ¼úÀÌ ¸ðµç ±¸°­ ¾ÏÀÇ 75%¸¦ ¾ß±âÇØ ÀÌ Áúȯ¿¡ °¡Àå Å« ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. Èí¿¬°ú °úÀ½ÀÌ °¢°¢ ±¸°­ ¾ÏÀÇ À§Ç輺À» Áõ°¡½ÃŰ´Â ¹Ý¸é, ±×µéÀÇ »óÇÕÈ¿°ú´Â ±× ¸î ¹èÀÎ °ÍÀ¸·Î ³ªÅ¸³ª¼­ °ñÃÊ¿¡ ¾ËÄÝ Áßµ¶À̶ó¸é Á¤»óÀÎÀÇ ¾à 30¹è ÀÌ»ó ÀÌȯÀ²ÀÌ ³ô¾ÆÁø´Ù. ±¸°­ ¾ÏÀÇ ÈçÇÑ Àü±¸ Áõ»óÀ¸·Î ¾Ë·ÁÁø ¹é¹ÝÁõÀº ±¸°­ Á¡¸·¿¡ Èò ¹éŸ¦ º¸ÀÌ´Â º´º¯À¸·Î ÀÌ ÁúȯÀÌ ¾ÏÁ¾À¸·Î ÁøÇàµÉ È®·üÀº 0.1%~36%ÀÇ ¸Å¿ì ´Ù¾çÇÑ ÆíÂ÷·Î º¸°íµÇ°í ÀÖÀ¸³ª ÀϹÝÀûÀ¸·Î´Â 10Áõ·Ê Áß 1Áõ·Ê°¡ ÀÌÇàµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. Àß ÀûÇÕµÇÁö ¾Ê´Â Ʋ´Ï³ª ¿À·¡ »ç¿ëÇÏ¿© ¸¶¸ðµÇ°í ³¯Ä«·Î¿öÁø ±Ý°ü µî¿¡ ÀÇÇÏ¿© Çù Á¡¸·À̳ª Çô, ¹«Ä¡¾Ç Ä¡Á¶Á¤ Á¡¸· µî¿¡ ¹ß»ýµÇ´Â ±Ë¾ç¼º º´º¯Àº Á¾±¹¿¡´Â ±¸°­ ¾ÏÀ¸·Î ÀüÀ̵DZ⠽¬¿î °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ¾î ÁÖ±âÀûÀÎ Ä¡°ú °ËÁøÀÌ ÇÊ¿äÇÏ´Ù. ±¸°­ ¾ÏÀÇ À§Çè ¿ä¼Ò Áß¿¡´Â À¯ÀüÀû ¿ä¼Òµµ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ƯÁ¤ Áý´Ü Áß¿¡´Â ¾ÏÀ» °¡Áö°í ÀÖ´Â °¡Á·ÀÌ ÀÖÀ¸¸é ±¸°­ ¾ÏÀÇ ¹ß»ý À§Ç輺ÀÌ ³ôÀº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. Èí¿¬°ú À½ÁÖ°¡ ±¸°­ ¾Ï ¹ß»ý¿¡ °¡Àå Áß¿äÇÑ ¿äÀÎÀ̱⠶§¹®¿¡ Áß´ÜÇϰųª ÃÖ¼ÒÇÑ ÁÙÀÌ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÏ´Ù. °Ç°­ÇÑ ½Ä»ýȰÀº ±¸°­ ¾ÏÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Ù. ½Å¼±ÇÑ °úÀÏÀ̳ª ³ì»ö ä¼Ò´Â ±¸°­ ¾Ï ¹ß»ý·üÀ» °¨¼Ò½Ãų ¼ö ÀÖ°í, ÀÌ´Â ºñŸ¹Î A, C, E°¡ ÇÔÀ¯µÈ À½½ÄÀÌ ¿¹¹æ È¿°ú¸¦ °®´Â´Ù´Â »ç½ÇÀ» µÞ¹ÞħÇÑ´Ù. ±¸°­ Á¡¸·À» µ¥ÀÏ Á¤µµÀÇ ¶ß°Å¿î À½½ÄÀ̳ª ÀڱؼºÀÇ À½½ÄÀº ÇÇÇϵµ·Ï ÇÏ´Â °ÍÀÌ ÁÁ´Ù. HPVÀÇ ¹ßÇöÀ̳ª P53 À¯Àü ÀÎÀÚÀÇ º¯À§¿Í °°Àº ƯÁ¤ À¯ÀüÇÐÀû ¶Ç´Â Ãʱ⠼¼Æ÷ º¯È­°¡ ±¸°­ ¾Ï°ú °ü·ÃÀÌ ÀÖ´Ù´Â ¹ß°ßÀº ÃÖ±Ù ÁÖ¸ñ¹Þ°í ÀÖ´Â ¿¬±¸ÀÌ´Ù. °¡±î¿î ¹Ì·¡¿¡´Â ±¸°­ ¾ÏÀÇ À§Ç輺ÀÌ ³ôÀº ȯÀÚÀÇ ±¸°­ Á¡¸·À» ÁÖ±âÀûÀ¸·Î °Ë»çÇϰųª Ãʱ⠼¼Æ÷ º¯È­¸¦ º¸À̴ ȯÀÚ¸¦ ÀÎÁöÇÏ´Â °ÍÀÌ °¡´ÉÇÒ °ÍÀÌ´Ù. ±¸°­ ¾ÏÀÇ Á¶±â ¹ß°ß°ú Ä¡·á¸¦ À§ÇÑ À¯¿ëÇÑ ±â¼úÀÇ °³¹ßÀº ÀÌ ºÐ¾ß¿¡¼­ ±â´ëµÈ´Ù. ±¸°­ ¾ÏÀº ¹ß»ý Ãʱ⿡´Â º°´Ù¸¥ Áõ»óÀ» º¸ÀÌÁö ¾Ê°í ¼­¼­È÷ ÁøÇàµÇ±â ¶§¹®¿¡ Á¶±â ¹ß°ßÀÌ ¹«Ã´ ¾î·Æ´Ù. ±¸°­ ¾Ç¾È¸é ¿µ¿ªÀÇ ¾ÏÀÇ Á¶±â ¹ß°ßÀº ¿©·¯ °¡Áö ÀÓ»óÀûÀÎ ¹ß°ßÀÌ ±âÃʰ¡ µÇ´Âµ¥ Ãʱ⿡´Â ´ë°³ ºÓÀº È«¹ÝÁõÀ» º¸À̸ç Á¡¸·ÀÌ °ÅÄ¥¾îÁö°í ¾à°£ À¶±âµÇ³ª À̶§´Â ¿°Áõ¼º º´¼Ò¿Í ºñ½ÁÇÏ¿© °¨º°ÀÌ °ï¶õÇÏ´Ù. ÀÌÈÄ ÁøÇàµÇ¾î ÀԾȿ¡ Èò ¸·ÀÌ »ý±â°Å³ª ÀÔ¾ÈÀÌ Çæ¾î ±Ë¾çÀÌ »ý±â°í º¸¸§ ÀÌ»ó ³´Áö ¾Ê°í Áö¼ÓµÇ´Â °æ¿ìµµ ÀÖ´Ù. ÀԾȿ¡ ¸¸¼ºÀûÀ¸·Î ¹é»ö º´¼Ò°¡ ÀÖ´Â °æ¿ì, ¸ñ¿¡ ¸Û¿ïÀÌ »ý±â°í ¾ø¾îÁöÁö ¾Ê´Â °æ¿ì ±¸°­ ¾ÏÀÌ ÀǽɵǹǷΠÁ» ´õ ¼¼¹ÐÇÑ Áø´ÜÀ» ¹Þ¾Æº¸´Â °ÍÀÌ ±ÇÀåµÇ¸ç Á¶±â Áø´Ü ½Ã »ýÁ¸À²Àº ÇöÀúÇÏ°Ô ³ô¾ÆÁö°Ô µÈ´Ù. ±¸°­ ¾Ï Ä¡·á ¹æ¹ýÀº ´ëÇ¥ÀûÀ¸·Î ¿Ü°úÀû ¼ö¼ú, ¹æ»ç¼± ¿ä¹ý, Ç×¾Ï ¿ä¹ýÀ¸·Î ÀÌ·ç¾îÁö¸ç ´Üµ¶À¸·Î ¶Ç´Â º¹ÇÕÀûÀ¸·Î ½ÃÇàµÈ´Ù. ÃÖ±Ù¿¡ ¸é¿ª ¿ä¹ý, ±¤ ¿¡³ÊÁö ¿ä¹ý µîÀÌ °³¹ßµÇ°í ÀÖÀ¸³ª ¾ÆÁ÷ ÀÓ»óÀûÀ¸·Î Ȱ¹ßÈ÷ ÀÌ¿ëµÇ°í ÀÖÁö´Â ¸øÇÏ´Ù. ±¸°­ ¾Ç¾È¸é ºÎÀ§ÀÇ Á¾¾çÀÇ ÀýÁ¦ ½Ã¿¡´Â Åë»ó ¾Ç¾È¸é ºÎÀ§ÀÇ °á¼ÕÀ¸·Î ±â´É Àå¾Ö¿Í ¾È¸ð ÃßÇü µîÀÇ ½É¹ÌÀûÀÎ ¼Õ»ó°ú ÀÌ¿¡ µû¸¥ Á¤½Å ½É¸®Àû ¹®Á¦Á¡À» ¾ß±âÇÒ ¼ö ÀÖ´Ù. ±¸°­ ¾Ï ÀýÁ¦¼ú ÈÄ ¾Ç°ñ ¹× ¿¬Á¶Á÷ °á¼ÕÀÌ ÀÖ´Â °æ¿ì¿¡ ¾Ç°ñ Àç°ÇÀ» ´Ü¼øÈ÷ º¹¿øÀ̶ó´Â °³³äÀ» ¶°³ª ½É¹ÌÀûÀ̰í ÀúÀÛ ±â´ÉÀÇ È¸º¹À̶ó´Â Â÷¿ø¿¡¼­ Àç°ÇÇÏ¿© »çȸÀûÀ¸·Î º¹±ÍÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
negative convergence The slight divergence of the visual axes when convergence is at rest, as when observing the far point or during sleep.
(05 Mar 2000)
far point of convergence The point to which the visual lines are directed when convergence is at rest.
(05 Mar 2000)
unit of convergence See: meter angle.
(05 Mar 2000)
unit of ocular convergence The amount of convergence required to view binocularly an object 1 meter distant and exerting 1 diopter of accommodation.
Synonym: unit of ocular convergence.
(05 Mar 2000)
American Cancer Society <address, organisation>
American Cancer Society, National Headquarters, 1599 Clifton Road, NE, Atlanta, GA 30329 USA.
Tel: 00 1 404 320-3333
(05 Feb 1998)
bladder cancer The most common warning sign of bladder cancer is blood in the urine. The diagnosis of bladder cancer is supported by findings in the medical history and examination, blood, urine, and X-ray tests, and confirmed with a biopsy (usually during a cystoscope exam). Treatment of bladder cancer depends on the growth, size, and location of the tumour.
(12 Dec 1998)
bladder cancer risks Smoking is a major risk factor. Cigarette smokers develop bladder cancer 2-3 times more often than do nonsmokers. Quitting smoking reduces the risk of bladder cancer, lung cancer, several other types of cancer, and a number of other diseases as well. Workers in some occupations are at higher risk of developing bladder cancer because of exposure to carcinogens (cancer-causing substances) in the workplace. These workers include people in the rubber, chemical, and leather industries, as well as hairstylists, machinists, metal workers, printers, painters, textile workers, and truck drivers.
(12 Dec 1998)
bone cancer <oncology> A general term to imply malignant tumour growth in bone.
(27 Sep 1997)
bovine cancer eye A malignant squamous cell carcinoma of cattle, especially the Hereford breed, that originates in the conjunctival mucous membranes or the surrounding skin; it occurs principally in range cattle having unpigmented skin around the eye and living in regions of intense sunlight.
(05 Mar 2000)
BRCA1 breast cancer susceptibility gene This mutated (changed) version of the BRCA1 gene makes a person susceptible to developing breast cancer.
(12 Dec 1998)
breast cancer <oncology> The uncontrolled growth of malignant breast tissue.
Breast cancer is currently the most common cancer in women and the leading cause of cancer-related death in the 15-54 age group.
Strong risk factors include a prior history for breast cancer or a positive family history for breast cancer.
Early detection is possible through the use of monthly breast self-examination, annual clinical exams and mammography.
WWW: cancerNET document for patients
WWW: cancerNET document for clinicians
(05 Jan 1998)
breast cancer susceptibility genes Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. However, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered.
(12 Dec 1998)
buyo cheek cancer betel cancer
cancer <oncology> The first historical description of this condition was in relation to breast carcinoma.
This is now a general term for more than 100 diseases that are characterised by uncontrolled, abnormal growth of cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body.
(18 Nov 1997)
cancer antigen 125 test Test for cell-surface antigen found on derivatives of coelomic epithelium. Elevated levels of this antigen are associated with ovarian malignancy and benign pelvic disease such as endometriosis.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • desk theory
    ʻ󰸷Ð
  • diluvial theory
    (ÁöÁú)È«¼ö¼³(³ë¾ÆÀÇ È«¼ö¸¦ Áö±¸ ¿ª»ç»ó ÃÖ´ëÀÇ »ç½Ç·Î º¸¸ç È­¼®À» È«¼ö·Î »ç¸êÇÑ »ý¹°ÀÇ À¯Ã¼·Î º½)
  • domino theory
    µµ¹Ì³ë ÀÌ·Ð(ÇÑ ³ª¶ó°¡ °ø»êÈ­µÇ¸é ÀÎÁ¢ ±¹°¡µéµµ °ø»êÈ­µÈ´Ù´Â)
  • field theory
    Àå·Ð;ÀåÀÇ ÀÌ·Ð
  • frontier orbital theory
    ÇÁ·ÐƼ¾î ÀüÀÚ ±Ëµµ ÀÌ·Ð
  • game theory
    °ÔÀÓÀÇ ÀÌ·Ð(ºÒÈ®Á¤ÇÑ ¿ä¼Ò Áß¿¡¼­ ÃÖ´ëÀÇ È¿°ú¸¦ ¿Ã¸®´Â ¼öÇÐÀû ÀÌ·Ð)
  • germ theory
    ¹èÁ¾¼³;¸Å±Õ¼³
  • group theory
    ±º·Ð
  • hit theory
    Ç¥Àû·Ð;Ãæ°Ý¼³
  • information theory
    Á¤º¸ÀÌ·Ð
  • interpretive semantics(theory)
    (¾ð)ÇØ¼® Àǹ̷Ð
  • nebular hypothesis(theory)
    (õ)(žç°èÀÇ)¼º¿î¼³
  • quantum theory
    ¾çÀÚ·Ð
  • stress theory
    (ij³ª´ÙÀÇ H,Selye ±³¼ö ÁÖâÀÇ)½ºÆ®·¹½º Çм³
  • theory
    Çм³;¼³;ÀÌ·Ð;(Ź»óÀÇ)°ø·Ð
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á